An urgent proposal for the immediate use of melatonin as an adjuvant to anti- SARS-CoV-2 vaccination
Abstract: Competition among pharmaceutical companies to develop safe and effective vaccines against SARS-CoV-2 is high. However, based on the prior experience with the influenza vaccine, up to 50% in lack of effectiveness would be found among healthy adults receiving effective vaccines against SARS-CoV-2. There is growing evidence that insufficient sleep may potentially be a pervasive and prominent factor accounting for this variability. Individuals experiencing total or partial sleep loss exhibit markedly reduced antigen-specific antibodies as compared to healthy sleepers. Besides, pre-vaccination sleep quality is also an important contributing factor. Several meta-analyses and expert consensus reports support the view that the chronobiotic/hypnotic properties of melatonin are useful in patients with primary sleep disorders to decrease sleep onset latency and to increase total sleep time. Hence, the prescription of melatonin for at least 2 weeks prior to vaccination can be a useful approach to improve sleep quality and to ensure that the vaccination is performed at a moment of optimal sleep conditions. Moreover, melatonin enhances the immune response to vaccines by increasing peripheral blood CD4+ T cells and IgG-expressing B cells. Administration of exogenous melatonin could increase the potency of the immune response and the duration of the immunity induced by the vaccine. Besides, melatonin could also prevent adverse effects of the vaccination due to its antioxidant and immunomodulatory properties. Therefore, the administration of melatonin from 2 weeks to at least 4 weeks after vaccination may constitute an effective means to enhance the efficacy of vaccination against SARS-CoV-2.
Autores principales: | , , |
---|---|
Formato: | Artículo biblioteca |
Idioma: | eng |
Publicado: |
ST-Bio-Life LLC
2021
|
Materias: | COVID-19, SARS-CoV-2, MELATONINA, INSOMNIO, SUEÑO, VACUNACION, |
Acceso en línea: | https://repositorio.uca.edu.ar/handle/123456789/13669 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:ucacris:123456789-13669 |
---|---|
record_format |
koha |
spelling |
oai:ucacris:123456789-136692022-03-31T18:56:20Z An urgent proposal for the immediate use of melatonin as an adjuvant to anti- SARS-CoV-2 vaccination Cardinali, Daniel Pedro Brown, Gregory M. Pandi Perumal, Seithikurippu R. COVID-19 SARS-CoV-2 MELATONINA INSOMNIO SUEÑO VACUNACION Abstract: Competition among pharmaceutical companies to develop safe and effective vaccines against SARS-CoV-2 is high. However, based on the prior experience with the influenza vaccine, up to 50% in lack of effectiveness would be found among healthy adults receiving effective vaccines against SARS-CoV-2. There is growing evidence that insufficient sleep may potentially be a pervasive and prominent factor accounting for this variability. Individuals experiencing total or partial sleep loss exhibit markedly reduced antigen-specific antibodies as compared to healthy sleepers. Besides, pre-vaccination sleep quality is also an important contributing factor. Several meta-analyses and expert consensus reports support the view that the chronobiotic/hypnotic properties of melatonin are useful in patients with primary sleep disorders to decrease sleep onset latency and to increase total sleep time. Hence, the prescription of melatonin for at least 2 weeks prior to vaccination can be a useful approach to improve sleep quality and to ensure that the vaccination is performed at a moment of optimal sleep conditions. Moreover, melatonin enhances the immune response to vaccines by increasing peripheral blood CD4+ T cells and IgG-expressing B cells. Administration of exogenous melatonin could increase the potency of the immune response and the duration of the immunity induced by the vaccine. Besides, melatonin could also prevent adverse effects of the vaccination due to its antioxidant and immunomodulatory properties. Therefore, the administration of melatonin from 2 weeks to at least 4 weeks after vaccination may constitute an effective means to enhance the efficacy of vaccination against SARS-CoV-2. 2022-03-22T12:59:34Z 2022-03-22T12:59:34Z 2021 Artículo Cardinali, D. P., Brown, G. M., Pandi Perumal, S. R. An urgent proposal for the immediate use of melatonin as an adjuvant to anti- SARS-CoV-2 vaccination [en línea]. Melatonin Research. 2021, 4 (1). doi: 10.32794/mr11250091. doi: 10.32794/mr11250091. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/13669 2641-0281 (online) https://repositorio.uca.edu.ar/handle/123456789/13669 10.32794/mr11250091 eng Acceso abierto http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf ST-Bio-Life LLC Melatonin Research Vol. 4, No.1, 2021 |
institution |
UCA |
collection |
DSpace |
country |
Argentina |
countrycode |
AR |
component |
Bibliográfico |
access |
En linea |
databasecode |
dig-uca |
tag |
biblioteca |
region |
America del Sur |
libraryname |
Sistema de bibliotecas de la UCA |
language |
eng |
topic |
COVID-19 SARS-CoV-2 MELATONINA INSOMNIO SUEÑO VACUNACION COVID-19 SARS-CoV-2 MELATONINA INSOMNIO SUEÑO VACUNACION |
spellingShingle |
COVID-19 SARS-CoV-2 MELATONINA INSOMNIO SUEÑO VACUNACION COVID-19 SARS-CoV-2 MELATONINA INSOMNIO SUEÑO VACUNACION Cardinali, Daniel Pedro Brown, Gregory M. Pandi Perumal, Seithikurippu R. An urgent proposal for the immediate use of melatonin as an adjuvant to anti- SARS-CoV-2 vaccination |
description |
Abstract:
Competition among pharmaceutical companies to develop safe and effective vaccines
against SARS-CoV-2 is high. However, based on the prior experience with the influenza
vaccine, up to 50% in lack of effectiveness would be found among healthy adults receiving
effective vaccines against SARS-CoV-2. There is growing evidence that insufficient sleep may
potentially be a pervasive and prominent factor accounting for this variability. Individuals
experiencing total or partial sleep loss exhibit markedly reduced antigen-specific antibodies as
compared to healthy sleepers. Besides, pre-vaccination sleep quality is also an important
contributing factor. Several meta-analyses and expert consensus reports support the view that
the chronobiotic/hypnotic properties of melatonin are useful in patients with primary sleep
disorders to decrease sleep onset latency and to increase total sleep time. Hence, the
prescription of melatonin for at least 2 weeks prior to vaccination can be a useful approach to
improve sleep quality and to ensure that the vaccination is performed at a moment of optimal
sleep conditions. Moreover, melatonin enhances the immune response to vaccines by
increasing peripheral blood CD4+ T cells and IgG-expressing B cells. Administration of
exogenous melatonin could increase the potency of the immune response and the duration of
the immunity induced by the vaccine. Besides, melatonin could also prevent adverse effects of
the vaccination due to its antioxidant and immunomodulatory properties. Therefore, the
administration of melatonin from 2 weeks to at least 4 weeks after vaccination may constitute
an effective means to enhance the efficacy of vaccination against SARS-CoV-2. |
format |
Artículo |
topic_facet |
COVID-19 SARS-CoV-2 MELATONINA INSOMNIO SUEÑO VACUNACION |
author |
Cardinali, Daniel Pedro Brown, Gregory M. Pandi Perumal, Seithikurippu R. |
author_facet |
Cardinali, Daniel Pedro Brown, Gregory M. Pandi Perumal, Seithikurippu R. |
author_sort |
Cardinali, Daniel Pedro |
title |
An urgent proposal for the immediate use of melatonin as an adjuvant to anti- SARS-CoV-2 vaccination |
title_short |
An urgent proposal for the immediate use of melatonin as an adjuvant to anti- SARS-CoV-2 vaccination |
title_full |
An urgent proposal for the immediate use of melatonin as an adjuvant to anti- SARS-CoV-2 vaccination |
title_fullStr |
An urgent proposal for the immediate use of melatonin as an adjuvant to anti- SARS-CoV-2 vaccination |
title_full_unstemmed |
An urgent proposal for the immediate use of melatonin as an adjuvant to anti- SARS-CoV-2 vaccination |
title_sort |
urgent proposal for the immediate use of melatonin as an adjuvant to anti- sars-cov-2 vaccination |
publisher |
ST-Bio-Life LLC |
publishDate |
2021 |
url |
https://repositorio.uca.edu.ar/handle/123456789/13669 |
work_keys_str_mv |
AT cardinalidanielpedro anurgentproposalfortheimmediateuseofmelatoninasanadjuvanttoantisarscov2vaccination AT browngregorym anurgentproposalfortheimmediateuseofmelatoninasanadjuvanttoantisarscov2vaccination AT pandiperumalseithikurippur anurgentproposalfortheimmediateuseofmelatoninasanadjuvanttoantisarscov2vaccination AT cardinalidanielpedro urgentproposalfortheimmediateuseofmelatoninasanadjuvanttoantisarscov2vaccination AT browngregorym urgentproposalfortheimmediateuseofmelatoninasanadjuvanttoantisarscov2vaccination AT pandiperumalseithikurippur urgentproposalfortheimmediateuseofmelatoninasanadjuvanttoantisarscov2vaccination |
_version_ |
1756276477394944000 |